Methodologies for in vitro and in vivo evaluation of efficacy of antifungal and antibiofilm agents and surface coatings against fungal biofilms
Open accessThe DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Abstract
Methodologies for in vitro and in vivo evaluation of efficacy of antifungal and antibiofilm agents and surface coatings against fungal biofilms – Unlike superficial fungal infections of the skin and nails, which are the most common (...)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hidden Killers: Human Fungal Infections
Brown, G. D., Denning, D. W., Gow, N. A. R., Levitz, S. M., Netea, M. G., & White, T. C. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004404 · Cited by 4,284
Self-citationEpidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174
Self-citationPierce, C. G., Uppuluri, P., Tristan, A. R., Wormley, F. L., Mowat, E., Ramage, G., & Lopez-Ribot, J. L. (2008) · Nature Protocols · doi:10.1038/nprot.2008.141 · Cited by 1,041 · cited 1×
“The most commonly used method is based on a static model using 96-well microtiter plates [78, 79], thereby quantifying microbial biomass or metabolic activity, using compounds such as crystal violet (CV), 2,3-bis (2-methoxy4-nitro-5-sulfophenyl)-5-[(phenylamino)carbonyl]-2H-tetrazolium hydroxide reduction (XTT), the m…”
MethodSelf-citationCandida biofilms on implanted biomaterials: a clinically significant problem
Ramage, G., MartÃnez, J. P., & López-Ribot, J. L. (2006) · FEMS Yeast Research · doi:10.1111/j.1567-1364.2006.00117.x · Cited by 575
Self-citationVerweij, P. E., Chowdhary, A., Melchers, W. J. G., & Meis, J. F. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ885 · Cited by 561
Self-citationCandida albicans Biofilms Produce Antifungal-Tolerant Persister Cells
LaFleur, M. D., Kumamoto, C. A., & Lewis, K. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00684-06 · Cited by 521
Drug/device combinations for local drug therapies and infection prophylaxis
Wu, P., & Grainger, D. W. (2006) · Biomaterials · doi:10.1016/j.biomaterials.2005.11.031 · Cited by 491
Sionov, E., Lee, H., Chang, Y. C., & Kwon-Chung, K. J. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1000848 · Cited by 479
Crespo, M., Vilar, E., Tsai, S.-Y., Chang, K., Amin, S., Srinivasan, T., Zhang, T., Pipalia, N. H., Chen, H. J., Witherspoon, M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4355 · Cited by 399 · cited 2×
“This and similar approaches will likely be used in the future for disease modeling and drug discovery [234].”
MethodAndes, D., Nett, J., Oschel, P., Albrecht, R., Marchillo, K., & Pitula, A. (2004) · Infection and Immunity · doi:10.1128/iai.72.10.6023-6031.2004 · Cited by 389
Self-citationPfaller, M. A., Sheehan, D. J., & Rex, J. H. (2004) · Clinical Microbiology Reviews · doi:10.1128/cmr.17.2.268-280.2004 · Cited by 352 · cited 3×
“The inclusion of dyes validated for specific detection of either vitality or mortality in the conventional AFST MIC setups can be highly relevant for assessing the fungicidal nature of an antifungal in a direct way [33, 49, 50].”
BackgroundSelf-citationKlepser, M. E., Ernst, E. J., Lewis, R. E., Ernst, M. E., & Pfaller, M. A. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.5.1207 · Cited by 338
Self-citationRecent insights into Candida albicans biofilm resistance mechanisms
Mathé, L., & Van Dijck, P. (2013) · Current Genetics · doi:10.1007/s00294-013-0400-3 · Cited by 271
Rosenberg, A., Ene, I. V., Bibi, M., Zakin, S., Segal, E. S., Ziv, N., Dahan, A. M., Colombo, A. L., Bennett, R. J., & Berman, J. (2018) · Nature Communications · doi:10.1038/s41467-018-04926-x · Cited by 270
Self-citationArendrup, M. C., Prakash, A., Meletiadis, J., Sharma, C., & Chowdhary, A. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00485-17 · Cited by 270 · cited 1×
“This has been recently addressed by the suggestion of more realistic, lower fluconazole breakpoints [25].”
BackgroundSelf-citationFungal echinocandin resistance
Walker, L. A., Gow, N. A. R., & Munro, C. A. (2010) · Fungal Genetics and Biology · doi:10.1016/j.fgb.2009.09.003 · Cited by 267
Self-citationPHR1 , a pH-Regulated Gene of Candida albicans , is Required for Morphogenesis
Saporito-Irwin, S. M., Birse, C. E., Sypherd, P. S., & Fonzi, W. A. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.2.601 · Cited by 264
The pH of the Host Niche Controls Gene Expression in and Virulence of Candida albicans
De Bernardis, F., Mühlschlegel, F. A., Cassone, A., & Fonzi, W. A. (1998) · Infection and Immunity · doi:10.1128/iai.66.7.3317-3325.1998 · Cited by 258
Patients with Long-Term Oral Carriage Harbor High-Persister Mutants of Candida albicans
LaFleur, M. D., Qi, Q., & Lewis, K. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00860-09 · Cited by 237 · cited 1×
“posed to make up a small proportion of some microbial cultures (either a biofilm or free-living culture) that can withstand the action of high doses of most antimicrobial agents and may facilitate the recurrence of microbial infections after treatment ceases [65, 66].”
BackgroundSynergistic Effect of Calcineurin Inhibitors and Fluconazole against Candida albicans Biofilms
Uppuluri, P., Nett, J., Heitman, J., & Andes, D. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01397-07 · Cited by 228
Self-citationMühlschlegel, F. A., & Fonzi, W. A. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.10.5960 · Cited by 209
Espinel-Ingroff, A., Fothergill, A., Peter, J., Rinaldi, M. G., & Walsh, T. J. (2002) · Journal of Clinical Microbiology · doi:10.1128/jcm.40.9.3204-3208.2002 · Cited by 203 · cited 1×
“For filamentous fungi, Espinel-Ingroff and colleagues [47] tested several conditions for optimum determination of MFC, which were subsequently adopted by other research groups [48].”
MethodSelf-citationSionov, E., Chang, Y. C., Garraffo, H. M., & Kwon-Chung, K. J. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00295-09 · Cited by 179
Minimum fungicidal concentrations of amphotericin B for bloodstream Candida species
Cantón, E., Pemán, J., Viudes, A., Quindós, G., Gobernado, M., & Espinel-Ingroff, A. (2003) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(02)00525-4 · Cited by 149 · cited 1×
“proposed a minor modification of the M27-A2 MIC procedure to allow MFC determinations based on the MIC test setup [38].”
MethodSelf-citationHata, K., Horii, T., Miyazaki, M., Watanabe, N.-A., Okubo, M., Sonoda, J., Nakamoto, K., Tanaka, K., Shirotori, S., Murai, N., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00366-11 · Cited by 149
Monteiro, M. C., de la Cruz, M., Cantizani, J., Moreno, C., Tormo, J. R., Mellado, E., De Lucas, J. R., Asensio, F., Valiante, V., Brakhage, A. A., et al. (2012) · SLAS Discovery · doi:10.1177/1087057111433459 · Cited by 144
Self-citationArendrup, M. C., Cuenca-Estrella, M., Lass-Flörl, C., & Hope, W. W. (2013) · Drug Resistance Updates · doi:10.1016/j.drup.2014.01.001 · Cited by 129
Self-citationSass, G., Nazik, H., Penner, J., Shah, H., Ansari, S. R., Clemons, K. V., Groleau, M.-C., Dietl, A.-M., Visca, P., Haas, H., et al. (2018) · Journal of Bacteriology · doi:10.1128/jb.00345-17 · Cited by 128
Self-citationSouza, A. C. R., Fuchs, B. B., Pinhati, H. M. S., Siqueira, R. A., Hagen, F., Meis, J. F., Mylonakis, E., & Colombo, A. L. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01177-15 · Cited by 121
Defining the frontiers between antifungal resistance, tolerance and the concept of persistence
Delarze, E., & Sanglard, D. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2015.10.001 · Cited by 118
Self-citationSionov, E., Chang, Y. C., & Kwon-Chung, K. J. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00694-13 · Cited by 112
In Vitro and In Vivo Activity of a Novel Antifungal Small Molecule against Candida Infections
Wong, S. S. W., Kao, R. Y. T., Yuen, K. Y., Wang, Y., Yang, D., Samaranayake, L. P., & Seneviratne, C. J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0085836 · Cited by 107 · cited 1×
“Mice systemic [183-188] [189] [190] [191, 192]”
Sanchez, A. A., Johnston, D. A., Myers, C., Edwards, J. E., Mitchell, A. P., & Filler, S. G. (2004) · Infection and Immunity · doi:10.1128/iai.72.1.598-601.2004 · Cited by 101 · cited 1×
“as well as other fungal pathogens [292-294].”
Self-citationThangamani, S., Maland, M., Mohammad, H., Pascuzzi, P. E., Avramova, L., Koehler, C. M., Hazbun, T. R., & Seleem, M. N. (2017) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2017.00004 · Cited by 90 · cited 1×
“Caenorhabditis elegans [100, 136, 161173] [166, 174, 175] [176]”
SCY-078 is fungicidal against Candida species in time-kill studies
Scorneaux, B., Angulo, D., Borroto-Esoda, K., Ghannoum, M., Peel, M., & Wring, S. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01961-16 · Cited by 88
Self-citationBen-Ami, R., Zimmerman, O., Finn, T., Amit, S., Novikov, A., Wertheimer, N., Lurie-Weinberger, M., & Berman, J. (2016) · mBio · doi:10.1128/mbio.00655-16 · Cited by 88
Self-citationAntifungal drug resistance in Candida species
Morace, G., Perdoni, F., & Borghi, E. (2014) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2014.09.002 · Cited by 80
De Cremer, K., Lanckacker, E., Cools, T. L., Bax, M., De Brucker, K., Cos, P., Cammue, B. P. A., & Thevissen, K. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04229-14 · Cited by 77
Self-citationUsing Combination Therapy to Thwart Drug Resistance
Hill, J. A., & Cowen, L. E. (2015) · Future Microbiology · doi:10.2217/fmb.15.68 · Cited by 75
Self-citationJohnson, C. C., Yu, A., Lee, H., Fidel, P. L., & Noverr, M. C. (2012) · Infection and Immunity · doi:10.1128/iai.00019-12 · Cited by 73
Jacobsen, I. D., Lüttich, A., Kurzai, O., Hube, B., & Brock, M. (2014) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dku198 · Cited by 73
Cordeiro, R. D. A., Evangelista, A. J. D. J., Serpa, R., Marques, F. J. D. F., Melo, C. V. S. D., Oliveira, J. S. D., Franco, J. D. S., Alencar, L. P. D., Bandeira, T. D. J. P. G., Brilhante, R. S. N., et al. (2016) · Microbiology · doi:10.1099/mic.0.000222 · Cited by 63
Gerstein, A. C., Rosenberg, A., Hecht, I., & Berman, J. (2016) · Microbiology · doi:10.1099/mic.0.000295 · Cited by 63
Self-citationKey issues concerning fungistatic versus fungicidal drugs
Graybill, J. R., Burgess, D. S., & Hardin, T. C. (1997) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/bf01575120 · Cited by 59 · cited 1×
“Therefore, fungicidal drugs are invaluable for this vulnerable patient population for eliminating fungal pathogens [32, 33].”
BackgroundCompetitive Fitness of Fluconazole-Resistant Clinical Candida albicans Strains
Popp, C., Hampe, I. A. I., Hertlein, T., Ohlsen, K., Rogers, P. D., & Morschhäuser, J. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00584-17 · Cited by 56
Vomocytosis of live pathogens from macrophages is regulated by the atypical MAP kinase ERK5
Gilbert, A. S., Seoane, P. I., Sephton-Clark, P., Bojarczuk, A., Hotham, R., Giurisato, E., Sarhan, A. R., Hillen, A., Velde, G. V., Gray, N. S., et al. (2017) · Science Advances · doi:10.1126/sciadv.1700898 · Cited by 54
Nishikawa, H., Fukuda, Y., Mitsuyama, J., Tashiro, M., Tanaka, A., Takazono, T., Saijo, T., Yamamoto, K., Nakamura, S., Imamura, Y., et al. (2017) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx020 · Cited by 51 · cited 1×
“Mice intratracheal/lung/ central nervous system [209-213] [147, 214-217] [218]”
Milbemycins: More than Efflux Inhibitors for Fungal Pathogens
Silva, L. V., Sanguinetti, M., Vandeputte, P., Torelli, R., Rochat, B., & Sanglard, D. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02040-12 · Cited by 49
Self-citationTati, S., Li, R., Puri, S., Kumar, R., Davidow, P., & Edgerton, M. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01851-13 · Cited by 36
Self-citationBreak, T. J., Desai, J. V., Natarajan, M., Ferre, E. M. N., Henderson, C., Zelazny, A. M., Siebenlist, U., Hoekstra, W. J., Schotzinger, R. J., Garvey, E. P., et al. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx352 · Cited by 34
Singulani, J. D. L., Scorzoni, L., Gomes, P. C., Nazaré, A. C., Polaquini, C. R., Regasini, L. O., Fusco-Almeida, A. M., & Mendes-Giannini, M. J. S. (2017) · Future Medicinal Chemistry · doi:10.4155/fmc-2017-0096 · Cited by 33
Scope and frequency of fluconazole trailing assessed using EUCAST in invasive Candida spp. isolates
Marcos-Zambrano, L. J., Escribano, P., Sánchez-Carrillo, C., Bouza, E., & Guinea, J. (2016) · Medical Mycology · doi:10.1093/mmy/myw033 · Cited by 33
Mohammad, H., Elghazawy, N. H., Eldesouky, H. E., Hegazy, Y. A., Younis, W., Avrimova, L., Hazbun, T., Arafa, R. K., & Seleem, M. N. (2018) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.7b00215 · Cited by 29
Coenye, T., De Vos, M., Vandenbosch, D., & Nelis, H. (2008) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2008.01956.x · Cited by 25
Self-citationThiazole derivatives act on virulence factors of Cryptococcus spp.
de Sá, N. P., de Barros, P. P., Junqueira, J. C., Vaz, J. A., de Oliveira, R. B., Rosa, C. A., Santos, D. A., & Johann, S. (2019) · Medical Mycology · doi:10.1093/mmy/myx158 · Cited by 13 · cited 1×
“moth) [127–139] [133, 140-144] [145-149] [150-155]”
Peters, B. M., Luna-Tapia, A., Tournu, H., Rybak, J. M., Rogers, P. D., & Palmer, G. E. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00084-17 · Cited by 12
Cited by
Fungal infections in humans: the silent crisis
Kainz, K., Bauer, M. A., Madeo, F., & Carmona-Gutierrez, D. (2020) · Microbial Cell · doi:10.15698/mic2020.06.718 · Cited by 369
Candida albicans biofilm growth and dispersal: contributions to pathogenesis
Wall, G., Montelongo-Jauregui, D., Vidal Bonifacio, B., Lopez-Ribot, J. L., & Uppuluri, P. (2019) · Current Opinion in Microbiology · doi:10.1016/j.mib.2019.04.001 · Cited by 263
“Notably, any and all these in vitro biofilm models reflect architectural features and properties of biofilms formed in vivo, in different animal models and also from those recovered from clinical samples, providing validation to these in vitro models[14].”
BackgroundMethodSelf-citationAntifungal therapy of Candida biofilms: Past, present and future
Ajetunmobi, O. H., Badali, H., Romo, J. A., Ramage, G., & Lopez-Ribot, J. L. (2023) · Biofilm · doi:10.1016/j.bioflm.2023.100126 · Cited by 52
“number of methodologies developed during the last couple of decades to study Candida biofilms [9,50].”
BackgroundSelf-citationPereira, P. F. S., de Paula e Silva, A. C. A., da Silva Pimentel, B. N. A., Pinatti, I. M., Simões, A. Z., Vergani, C. E., Barreto-Vieira, D. F., da Silva, M. A. N., Miranda, M. D., Monteiro, M. E. S., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-11902-5 · Cited by 20
Dasilva, M. A., Andrada, K. F. C., Torales, M. M., Hughes, I. M., Pez, P., García-Martínez, J. C., & Paraje, M. G. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02415-6 · Cited by 16
Metadata
- Authors
- Van Dijck, P., Sjollema, J., Camue, B. P. A., Lagrou, K., Berman, J., d’Enfert, C., Andes, D. R., Arendrup, M. C., Brakhage, A. A., Calderone, R., Cantón, E., Coenye, T., Cos, P., Cowen, L. E., Edgerton, M., Espinel-Ingroff, A., Filler, S. G., Ghannoum, M., A.R. Gow, N., Haas, H., Jabra-Rizk, M. A., Johnson, E. M., Lockhart, S. R., Lopez-Ribot, J. L., Maertens, J., Munro, C. A., Nett, J. E., Nobile, C. J., Pfaller, M. A., Ramage, G., Sanglard, D., Sanguinetti, M., Spriet, I., Verweij, P. E., Warris, A., Wauters, J., Yeaman, M. R., Zaat, S. A. J., & Thevissen, K.
- Venue
- Microbial Cell
- Publisher
- Shared Science Publishers OG
- Published
- 2018-07-02
- Volume
- 5
- Issue
- 7
- Pages
- 300-326
- ISSN
- 2311-2638 (ISSN-L)
- OpenAlex
- W2809506570
- Cited by
- 129
- References
- 56
- FWCI
- 9.68
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.